Jaime Kulisevsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9512755/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
2	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines. Movement Disorders, 2012, 27, 349-356.	3.9	1,908
3	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PDâ€MCI. Movement Disorders, 2011, 26, 1814-1824.	3.9	649
4	Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurology, The, 2015, 14, 518-531.	10.2	387
5	Parkinson's disease ognitive rating scale: A new cognitive scale specific for Parkinson's disease. Movement Disorders, 2008, 23, 998-1005.	3.9	264
6	Cognitive impairment and dementia in Parkinson's disease. Neurobiology of Disease, 2012, 46, 590-596.	4.4	198
7	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. JAMA Neurology, 2017, 74, 216.	9.0	171
8	Minor hallucinations occur in drugâ€naive Parkinson's disease patients, even from the premotor phase. Movement Disorders, 2016, 31, 45-52.	3.9	167
9	Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment. Movement Disorders, 2009, 24, 1103-1110.	3.9	159
10	Role of Dopamine in Learning and Memory. Drugs and Aging, 2000, 16, 365-379.	2.7	152
11	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	2.2	149
12	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients. Movement Disorders, 2000, 15, 613-626.	3.9	148
13	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disorders, 2012, 27, 393-399.	3.9	144
14	Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain, 1996, 119, 2121-2132.	7.6	142
15	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	3.6	128
16	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.5	125
17	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. Parkinsonism and Related Disorders, 2016, 25, 58-64.	2.2	122
18	Cognitive impairment in nondemented Parkinson's disease. Movement Disorders, 2011, 26, 2483-2495.	3.9	115

#	Article	IF	CITATIONS
19	Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson's Disease. PLoS ONE, 2013, 8, e54980.	2.5	112
20	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	11.6	90
21	Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 290-296.	2.2	87
22	N370S <i>â€GBA1</i> mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Movement Disorders, 2017, 32, 1409-1422.	3.9	86
23	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism and Related Disorders, 2015, 21, 871-876.	2.2	79
24	Measuring functional impact of cognitive impairment: Validation of the Parkinson's Disease Cognitive Functional Rating Scale. Parkinsonism and Related Disorders, 2013, 19, 812-817.	2.2	69
25	Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. Movement Disorders, 2007, 22, 62-67.	3.9	67
26	COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurology, 2016, 16, 26.	1.8	66
27	Predicting dementia development in Parkinson's disease using Bayesian network classifiers. Psychiatry Research - Neuroimaging, 2013, 213, 92-98.	1.8	64
28	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. Clinical Neuropharmacology, 2014, 37, 9-16.	0.7	62
29	Parkinson's disease ognitive rating scale: Psychometrics for mild cognitive impairment. Movement Disorders, 2013, 28, 1376-1383.	3.9	58
30	Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. Movement Disorders, 2019, 34, 78-86.	3.9	58
31	Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired Incentive Processing. Journal of Neuroscience, 2014, 34, 5918-5926.	3.6	55
32	Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson's Disease, 2017, 2017, 1-8.	1.1	53
33	The tools of the trade: A state of the art "How to Assess Cognition―in the patient with Parkinson's disease. Movement Disorders, 2014, 29, 584-596.	3.9	52
34	Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. Advances in Therapy, 2018, 35, 515-522.	2.9	47
35	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the diseaseâ€. Human Molecular Genetics, 2015, 24, 2023-2034.	2.9	45
36	Regional Overlap of Pathologies in Lewy Body Disorders. Journal of Neuropathology and Experimental Neurology, 2017, 76, 216-224.	1.7	45

#	Article	IF	CITATIONS
37	Apathy in Parkinson's Disease: More Than Just Executive Dysfunction. Journal of the International Neuropsychological Society, 2013, 19, 571-582.	1.8	43
38	Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2020, 74, 43-49.	2.2	43
39	Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes. Brain Imaging and Behavior, 2017, 11, 1334-1342.	2.1	42
40	Levodopa and executive performance in Parkinson's disease: A randomized study. Journal of the International Neuropsychological Society, 2008, 14, 832-841.	1.8	41
41	Nonâ€motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. European Journal of Neurology, 2020, 27, 1210-1223.	3.3	40
42	A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. Human Brain Mapping, 2019, 40, 3233-3242.	3.6	38
43	New Subtype of Spinocerebellar Ataxia With Altered Vertical Eye Movements Mapping to Chromosome 1p32. JAMA Neurology, 2013, 70, 764.	9.0	36
44	Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III. Dementia and Geriatric Cognitive Disorders, 2016, 41, 243-250.	1.5	35
45	Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease. Parkinsonism and Related Disorders, 2017, 44, 95-100.	2.2	33
46	Mild cognitive impairment in Parkinson's disease. Journal of Neural Transmission, 2019, 126, 897-904.	2.8	33
47	Is all cognitive impairment in Parkinson's disease "mild cognitive impairment�. Journal of Neural Transmission, 2011, 118, 1185-1190.	2.8	32
48	MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOE ɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	2.6	32
49	Striatal hypometabolism in premanifest and manifest Huntington's disease patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2183-2189.	6.4	32
50	Adenosine A _{2A} -Receptor Antagonism and Pathophysiology of Parkinson's Disease and Drug-Induced Movement Disorders. European Neurology, 2012, 67, 4-11.	1.4	31
51	A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinson's Disease, 2021, 11, 187-198.	2.8	31
52	Robot-induced hallucinations in Parkinson's disease depend on altered sensorimotor processing in fronto-temporal network. Science Translational Medicine, 2021, 13, .	12.4	29
53	Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker. Parkinsonism and Related Disorders, 2019, 68, 22-25.	2.2	28
54	White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease. NeuroImage: Clinical, 2019, 24, 101965.	2.7	27

#	Article	IF	CITATIONS
55	Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2012, 34, 312-318.	1.5	24
56	Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. Frontiers in Psychiatry, 2018, 9, 465.	2.6	24
57	Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease. Neurobiology of Disease, 2019, 124, 29-35.	4.4	24
58	Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial. Journal of Neural Transmission, 2014, 121, 357-366.	2.8	23
59	Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Parkinson's Disease, 2018, 2018, 1-5.	1.1	22
60	The impact of bilingualism on brain structure and function in Huntington's disease. Parkinsonism and Related Disorders, 2019, 60, 92-97.	2.2	22
61	Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. Movement Disorders, 2017, 32, 165-169.	3.9	19
62	Structural brain correlates of dementia in Huntington's disease. Neurolmage: Clinical, 2020, 28, 102415.	2.7	19
63	Parkinson's Disease: From Genetics to Clinical Practice. Current Genomics, 2014, 14, 560-567.	1.6	19
64	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. Drugs and Aging, 2015, 32, 401-407.	2.7	18
65	Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease. NeuroImage: Clinical, 2019, 23, 101900.	2.7	18
66	An active cognitive lifestyle as a potential neuroprotective factor in Huntington's disease. Neuropsychologia, 2019, 122, 116-124.	1.6	17
67	Predictors of clinically significant quality of life impairment in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 118.	5.3	17
68	Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. Journal of Parkinson's Disease, 2014, 4, 585-589.	2.8	15
69	Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1111-1116.	6.4	15
70	Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease. American Journal of Neuroradiology, 2019, 40, 1464-1468.	2.4	15
71	CLU rs11136000 Promotes Early Cognitive Decline in Parkinson's Disease. Movement Disorders, 2020, 35, 508-513.	3.9	15
72	Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinson's disease patients and its association with cognitive decline. Brain Imaging and Behavior, 2020, 14, 321-328.	2.1	14

#	Article	IF	CITATIONS
73	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.7	13
74	Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease. Journal of Neurology, 2020, 267, 1527-1535.	3.6	13
75	Structural brain correlates of irritability and aggression in early manifest Huntington's disease. Brain Imaging and Behavior, 2021, 15, 107-113.	2.1	13
76	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.6	13
77	Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline. Frontiers in Neurology, 2018, 9, 394.	2.4	12
78	Impaired face-like object recognition in premanifest Huntington's disease. Cortex, 2020, 123, 162-172.	2.4	12
79	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. Journal of Neurology, 2021, 268, 3400-3408.	3.6	12
80	Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters. Clinical Nuclear Medicine, 2019, 44, e1-e5.	1.3	11
81	Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease. Parkinsonism and Related Disorders, 2021, 85, 91-94.	2.2	11
82	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. ENeurologicalSci, 2017, 8, 44-53.	1.3	10
83	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	2.5	10
84	Efficacy of trazodone in antipsychotic-induced akathisia resistant to conventional treatment. Parkinsonism and Related Disorders, 2012, 18, 902-903.	2.2	9
85	Parkinson's Disease—Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment. Journal of the Neurological Sciences, 2016, 361, 66-71.	0.6	9
86	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	2.6	9
87	Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). Parkinsonism and Related Disorders, 2017, 43, 73-77.	2.2	8
88	Historical crossroads in the conceptual delineation of apathy in Parkinson's disease. Brain, 2018, 141, 613-619.	7.6	8
89	Reduced striatoâ€cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients. Human Brain Mapping, 2018, 39, 54-71.	3.6	7
90	Cognitive and behavioral assessment in Parkinson's disease. Expert Review of Neurotherapeutics, 2019, 19, 613-622.	2.8	7

#	Article	IF	CITATIONS
91	A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. Brain Sciences, 2020, 10, 176.	2.3	7
92	Intracortical surfaceâ€based MR diffusivity to investigate neurologic and psychiatric disorders: a review. Journal of Neuroimaging, 2022, 32, 28-35.	2.0	7
93	Emerging Role of Safinamide in Parkinson's Disease Therapy. European Neurological Review, 2015, 9, 108.	0.5	7
94	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. Npj Parkinson's Disease, 2022, 8, 17.	5.3	7
95	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. BMC Neurology, 2021, 21, 477.	1.8	7
96	Cortical Thinning Associated with Age and CSF Biomarkers in Early Parkinson's Disease Is Modified by the SNCA rs356181 Polymorphism. Neurodegenerative Diseases, 2018, 18, 233-238.	1.4	6
97	Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson's disease. Behavioural Brain Research, 2019, 372, 112039.	2.2	6
98	The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates. Frontiers in Neurology, 2020, 11, 240.	2.4	6
99	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2165-2174.	6.4	5
100	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. Diagnostics, 2022, 12, 1147.	2.6	5
101	Apathy: who cares?. Lancet Neurology, The, 2015, 14, 465.	10.2	4
102	Neural signatures of predictive language processing in Parkinson's disease with and without mild cognitive impairment. Cortex, 2021, 141, 112-127.	2.4	4
103	Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington's Disease. Clinical Neuroradiology, 2022, 32, 1077-1085.	1.9	4
104	A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene. Stem Cell Research, 2019, 38, 101482.	0.7	3
105	Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease. Neurotoxicity Research, 2019, 35, 563-574.	2.7	3
106	Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. Journal of Neurology, 2020, 267, 3400-3410.	3.6	3
107	Safinamide – A Unique Treatment Targeting Both Dopaminergic and Non-Dopaminergic Systems. European Neurological Review, 2016, 11, 101.	0.5	3
108	Measuring the functional impact of cognitive impairment in Huntington's disease. Journal of Neurology, 2022, 269, 3541-3549.	3.6	3

#	Article	IF	CITATIONS
109	MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. Diagnostics, 2022, 12, 55.	2.6	3
110	A collection of three integration-free iPSCs derived from old male and female healthy subjects. Stem Cell Research, 2020, 42, 101663.	0.7	2
111	Advances with MRI in Parkinson disease. Neurology, 2012, 79, 2222-2223.	1.1	1
112	Generation of an integration-free iPSC line, ICCSICi005-A, derived from a Parkinson's disease patient carrying the L444P mutation in the GBA1 gene. Stem Cell Research, 2019, 40, 101578.	0.7	1
113	Autoscopic phenomena as an atypical psychiatric presentation of Huntington's disease: A case report including longitudinal clinical and neuroimaging data. Cortex, 2020, 125, 299-306.	2.4	1
114	Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1567-1574.	2.8	1
115	Rasagiline for the treatment of parkinsonism in Huntington's disease. Parkinsonism and Related Disorders, 2015, 21, 340-342.	2.2	Ο
116	Author response to Wang et al. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment?. Parkinsonism and Related Disorders, 2020, 77, 159.	2.2	0
117	Mild Cognitive Impairment in Parkinson's Disease. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 29-51.	0.3	0